Am J Clin Oncol

1. SHEMBESH RH, Beshr MS, Elhadi M
   Letter to Editor on Qureshi et al. Efficacy and Safety of Abemaciclib in Combination with Endocrine Therapy for HR+/HER2- Advanced or Metastatic Breast Cancer a Systematic Review and Meta-Analysis, Am J Clin Oncol, 2025, 48(1).
   Am J Clin Oncol. 2025;48:477-478.
   

   >> Share

   
   

   
   Am J Epidemiol

2. AL-KASSAB-CORDOVA A, Humphreys ABC, Parra CO, Feychting M, et al
   Endocrine therapies and mortality risk in postmenopausal women with breast cancer: benchmarking an observational analysis against a randomized trial.
   Am J Epidemiol. 2025 Aug 21:kwaf183. doi: 10.1093.
   

   >> Share

   
   

   
   Am J Surg

3. NTOWE KW, Thomas SM, Dalton JC, Olunuga E, et al
   The association of race and ethnicity with risk-reducing mastectomies in patients with non-BRCA mutations.
   Am J Surg. 2025;247:116485.
   

   >> Share

   
   

   
   Am J Surg Pathol

4. COLARD-THOMAS J, Pialoux-Guibal A, Gemival P, Maran-Gonzalez A, et al
   Confocal Laser Microscopy for Intraoperative Margin Assessment in Breast-Conserving Surgery: A New Procedure in the Pathology Laboratory Workflow.
   Am J Surg Pathol. 2025;49:909-922.
   

   >> Share

   
   
5. BACHERT SE, Onken AM, Cleary AS, Nakhlis F, et al
   The Clinicopathologic Features of Inflammatory Breast Carcinoma (IBC) With Lobular Features.
   Am J Surg Pathol. 2025;49:882-889.
   

   >> Share

   
   

   
   Ann Surg Oncol

6. MARIN C, Strawderman M, Peterson D, Cheng Z, et al
   Biology is Queen: The Oncotype DX 21-Gene Recurrence Score Has Stronger Prognostic Ability than Lymph Node Burden for Patients with Breast Cancer.
   Ann Surg Oncol. 2025 Aug 20. doi: 10.1245/s10434-025-18086.
   

   >> Share

   
   
7. TASHJIAN NL, Hoskin TL, Leon-Ferre RA, Boughey JC, et al
   ASO Author Reflections: Survival of Patients with HER2-Positive Breast Cancer After Neoadjuvant Chemotherapy Based on Presenting Clinical Stage and Response to Neoadjuvant Chemotherapy.
   Ann Surg Oncol. 2025 Aug 20. doi: 10.1245/s10434-025-18188.
   

   >> Share

   
   
8. CHAKRABORTY MA, Sherwani ZK, Narra LR, Abou Yehia Z, et al
   Preoperative Radiation Boost Results in Low Rates of Re-excision and Reduced Locoregional Treatment Time in Breast Cancer Patients.
   Ann Surg Oncol. 2025 Aug 20:10.1245/s10434-025-18089.
   

   >> Share

   
   
9. MOHAN SC, Chen JH, Tidwell RSS, Kai M, et al
   ASO Visual Abstract: Investigating the Prognostic Impact of Postpartum Diagnosis in Women with De Novo Stage IV Inflammatory Breast Cancer.
   Ann Surg Oncol. 2025 Aug 21. doi: 10.1245/s10434-025-18098.
   

   >> Share

   
   
10. VETTER CD, C Boughey J
    ASO Author Reflections: Refining Prognostic Staging in De Novo Metastatic Breast Cancer: Validation, Limitations, and Future Directions.
    Ann Surg Oncol. 2025 Aug 23. doi: 10.1245/s10434-025-18113.
    

    >> Share

    
    
11. MUKHTAR RA, Dimitroff K, Yau C, Chien AJ, et al
    ASO Visual Abstract: Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial.
    Ann Surg Oncol. 2025 Aug 23. doi: 10.1245/s10434-025-18104.
    

    >> Share

    
    
12. VAN HASSEL J, Dimitroff K, Yau C, Mukhtar R, et al
    Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial.
    Ann Surg Oncol. 2025 Aug 23. doi: 10.1245/s10434-025-17933.
    

    >> Share

    
    
13. SERRES SK, Saxon-Filipe S, Schwartz T
    Complementary and Alternative Medicine in Breast Cancer: Considerations for the Breast Surgical Oncologist.
    Ann Surg Oncol. 2025 Aug 23. doi: 10.1245/s10434-025-17850.
    

    >> Share

    
    
14. NAASEH A, Tang SX, Maytin-Hevia AR, Wu N, et al
    ASO Visual Abstract: Are Broadened Guidelines Improving Our Detection of Pathologic Genetic Mutations in Breast Cancer Patients? A 5-Year Comparative Analysis of American Society of Breast Surgeons and National Comprehensive Cancer Network Guidelines.
    Ann Surg Oncol. 2025 Aug 23. doi: 10.1245/s10434-025-18182.
    

    >> Share

    
    
15. LYONS W, Fish EM, Bleicher RJ, Chang C, et al
    Management and Outcomes in Patients with Breast Cancer with 1-of-1 and 2-of-2 Positive Sentinel Nodes.
    Ann Surg Oncol. 2025 Aug 23. doi: 10.1245/s10434-025-18097.
    

    >> Share

    
    
16. AMBURN T, Downs-Canner S
    ASO Author Reflections: Nipple-Sparing Mastectomy for Breast Cancer Patients with Nipple Discharge.
    Ann Surg Oncol. 2025 Aug 23. doi: 10.1245/s10434-025-18078.
    

    >> Share

    
    
17. MUNCK F, Jensen MB, Hawaz-Ali R, Tvedskov THF, et al
    Oncologic First Events in Breast Cancer Patients After Targeted Axillary Dissection.
    Ann Surg Oncol. 2025 Aug 20. doi: 10.1245/s10434-025-18068.
    

    >> Share

    
    
18. CHICHURA AM, Chen X, Nelis M, Kopicky L, et al
    Neoadjuvant Chemotherapy is Associated with Worse 5-Year Overall Survival in Patients with Metaplastic Breast Cancer Compared with Primary Surgery: A National Cancer Database Analysis.
    Ann Surg Oncol. 2025 Aug 20. doi: 10.1245/s10434-025-18085.
    

    >> Share

    
    
19. MALHOTRA S, Choi DX, Sevilimedu V, Greenup RA, et al
    ASO Author Reflections: Medicaid's Impact on Breast Cancer.
    Ann Surg Oncol. 2025 Aug 19. doi: 10.1245/s10434-025-18107.
    

    >> Share

    
    
20. GHASEMI F, Young J, Asaoka M, Takabe K, et al
    ASO Author Reflections: Refining Breast Cancer Staging to More Accurately Reflect Disease Biology.
    Ann Surg Oncol. 2025 Aug 19. doi: 10.1245/s10434-025-18167.
    

    >> Share

    
    

    
    BMC Cancer

21. XING B, Gu C, Fu C, Zhang B, et al
    Diagnostic performance of ultrasound S-Detect technology in evaluating BI-RADS-4 breast nodules 20 mm.
    BMC Cancer. 2025;25:1306.
    

    >> Share

    
    
22. TAIWO R, Harary PM, Trinh TTH, Granucci M, et al
    Adaptive cohort design and LAT1 expression scale: study protocol for a Phase 2a trial of QBS72S in breast cancer brain metastases.
    BMC Cancer. 2025;25:1316.
    

    >> Share

    
    
23. LI SY, Li YM, Fang YQ, Jin ZY, et al
    Contrast-enhanced ultrasound radiomics model for predicting axillary lymph node metastasis and prognosis in breast cancer: a multicenter study.
    BMC Cancer. 2025;25:1315.
    

    >> Share

    
    
24. SREENATH ND, Pandalanghat S, Kapoor A, Govind R, et al
    A comparative analysis of Palbociclib and Ribociclib in metastatic hormone receptor-positive, HER2-negative breast cancer: a prospective mid term follow-Up study from an Indian cohort.
    BMC Cancer. 2025;25:1337.
    

    >> Share

    
    
25. ARAUJO CFM, Nunes LC, Murta-Nascimento C, Bragagnoli AC, et al
    Metformin for the treatment of breast cancer: a scoping review of randomized clinical trials.
    BMC Cancer. 2025;25:1352.
    

    >> Share

    
    
26. LI JD, Deng LL, Luo JY, Mo CH, et al
    The role of collagen type VI alpha 6 chain as a potential tumor suppressor in breast cancer: an immune regulation perspective.
    BMC Cancer. 2025;25:1363.
    

    >> Share

    
    
27. WANG Y, Wang L, Yu B, Wen S, et al
    Global, regional, and national burden of male breast cancer and predictions in the next 30 years: a systematic analysis of the global burden of disease study 2021.
    BMC Cancer. 2025;25:1344.
    

    >> Share

    
    
28. LIAN W, Li L, Hong C, Chen D, et al
    Impact of ovarian function suppression on prognosis in premenopausal patients with HR+/HER2 + early-stage breast cancer: a multi-center retrospective study.
    BMC Cancer. 2025;25:1331.
    

    >> Share

    
    

    
    Br J Cancer

29. STOER NC, Vangen S, Singh D, Fortner RT, et al
    Correction: Menopausal hormone therapy and breast cancer risk: a population-based cohort study of 1.3 million women in Norway.
    Br J Cancer. 2025 Aug 20. doi: 10.1038/s41416-025-03038.
    

    >> Share

    
    

    
    Breast Cancer

30. OSHI M, Sasamoto M, Isoda M, Kawashima K, et al
    Patient satisfaction on prescription refill systems for breast cancer patients in Japan using a digital self-administered survey.
    Breast Cancer. 2025 Aug 26. doi: 10.1007/s12282-025-01761.
    

    >> Share

    
    
31. TAKAHASHI M, Yasojima H, Osako T, Inoue K, et al
    Overall survival and subsequent therapy patterns in Japanese patients with ER+/HER2- advanced breast cancer treated with palbociclib plus letrozole in the first-line setting: a final analysis.
    Breast Cancer. 2025 Aug 21. doi: 10.1007/s12282-025-01760.
    

    >> Share

    
    
32. ZHANG L, Li B, Wang R, Li J, et al
    Prospective randomized-controlled trial: efficacy of 37 degrees C-preheated thermoplastic elastomer (TPE) bolus in postoperative radiotherapy for breast cancer patients.
    Breast Cancer. 2025 Aug 20. doi: 10.1007/s12282-025-01763.
    

    >> Share

    
    
33. RAY PP
    Enhancing breast cancer care through reasoning-aware LLMs: quality evaluation and risk prediction.
    Breast Cancer. 2025 Aug 20. doi: 10.1007/s12282-025-01756.
    

    >> Share

    
    
34. HUNG CS, Cheng YT, Li RH, Hillman CH, et al
    Effect of exercise interventions on cognitive function in breast cancer patients and survivors: a systematic review with meta-analysis.
    Breast Cancer. 2025 Aug 18. doi: 10.1007/s12282-025-01757.
    

    >> Share

    
    

    
    Breast Cancer (Dove Med Press)

35. LIN Z, Huang F, Wei L, Liao X, et al
    Predicting Human Epidermal Growth Factor Receptor 2 Expression in Breast Cancer Based on Radiomics of MRI Habitat and US.
    Breast Cancer (Dove Med Press). 2025;17:711-725.
    

    >> Share

    
    
36. XU X, Han Q, Qiu S, Gao S, et al
    Mechanisms and Management of Albumin-Paclitaxel-Induced Peripheral Neuropathy in Breast Cancer.
    Breast Cancer (Dove Med Press). 2025;17:693-709.
    

    >> Share

    
    

    
    Breast Cancer Res

37. DANKNER M, Ouellet V, Lafon J, Ezzeddine R, et al
    Cold-inducible RNA-binding protein is associated with subtype-specific breast cancer patient outcomes.
    Breast Cancer Res. 2025;27:149.
    

    >> Share

    
    
38. PATEL R, Weil E, Bugamelli S, Carroll E, et al
    Evaluation and management of incomplete ovarian function suppression in premenopausal breast cancer patients receiving anti-hormone therapy.
    Breast Cancer Res. 2025;27:147.
    

    >> Share

    
    
39. KLAHR MP, Faheem K, Raghunathan RR, Wooster M, et al
    Association between hyperglycemia and the development of chemotherapy induced peripheral neuropathy among patients with breast cancer in the control trial.
    Breast Cancer Res. 2025;27:150.
    

    >> Share

    
    
40. HAMILTON E, Pluard T, Wang JS, Morikawa A, et al
    Phase 1/2 study of H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive, HER2-negative breast cancer.
    Breast Cancer Res. 2025;27:151.
    

    >> Share

    
    
41. WESTENEND PJ, Meurs C, Fernandez G, Prastawa M, et al
    External validation of precisebreast, a digital prognostic test for predicting breast cancer recurrence, in an early-stage cohort from the Netherlands.
    Breast Cancer Res. 2025;27:152.
    

    >> Share

    
    

    
    Breast Cancer Res Treat

42. NOLAN L, Huan H, McDonnell W, Walsh S, et al
    The impact of mammographic breast density on locoregional recurrence in breast cancer: a systematic review and meta-analysis.
    Breast Cancer Res Treat. 2025 Aug 25. doi: 10.1007/s10549-025-07804.
    

    >> Share

    
    
43. BELTRAN-BLESS AA, Saunders D, Clemons L, Machado I, et al
    Patient perceptions around the use of clinico-pathologic and genomic tools in the management of early breast cancer.
    Breast Cancer Res Treat. 2025 Aug 21. doi: 10.1007/s10549-025-07797.
    

    >> Share

    
    
44. PATEL R, Fukui J, Klein P, Moshier E, et al
    Randomized phase II comparison of single-agent carboplatin versus combination of carboplatin and everolimus for advanced triple negative breast cancer.
    Breast Cancer Res Treat. 2025 Aug 16. doi: 10.1007/s10549-025-07802.
    

    >> Share

    
    
45. COHN JG, Locke SC, Herring KW, Dent SF, et al
    Palliative care use and end-of-life care quality in HR+/HER2- metastatic breast cancer.
    Breast Cancer Res Treat. 2025 Aug 16. doi: 10.1007/s10549-025-07805.
    

    >> Share

    
    
46. UMUTONI V, Sun Y, Freeman JQ, Zhao F, et al
    Quality of life during the COVID-19 pandemic and survival outcomes among breast cancer survivors.
    Breast Cancer Res Treat. 2025 Aug 15. doi: 10.1007/s10549-025-07808.
    

    >> Share

    
    

    
    Cancer

47. CHEN M, Lin Z, Chen X, Zhang J, et al
    Feasibility and accuracy of targeted axillary dissection by carbon tattooing in biopsy-proven node-positive breast cancer: A prospective study.
    Cancer. 2025;131:e70047.
    

    >> Share

    
    
48. NIERENGARTEN MB
    Endocrine therapy may be warranted in patients with ER-low, early-stage breast cancer.
    Cancer. 2025;131:e70002.
    

    >> Share

    
    

    
    Cancer Epidemiol Biomarkers Prev

49. DONZELLA SM, Rogers M, O'Brien KM, Von Holle A, et al
    Sedentary time and breast cancer risk in the Sister Study Cohort.
    Cancer Epidemiol Biomarkers Prev. 2025.
    

    >> Share

    
    

    
    Cancer Lett

50. LI C, Gao T, Zhao Q, Li Z, et al
    Inhibition of CPT1A activates the cGAS/STING pathway to enhance neutrophil-mediated tumor abrogation in triple-negative breast cancer.
    Cancer Lett. 2025;633:217991.
    

    >> Share

    
    

    
    Cancer Res

51. ZHU XZ, Zhang HY, Zhou YF, Chen YY, et al
    Subtyping-Directed Precision Treatment Refines Traditional One-Size-Fits-All Therapy for HR+/HER2- Breast Cancer.
    Cancer Res. 2025 Aug 18. doi: 10.1158/0008-5472.CAN-24-5002.
    

    >> Share

    
    

    
    Carcinogenesis

52. WANG J, Wang D, Zhang X, Xu X, et al
    HECTD3 E3 ligase mediates ubiquitination of AKT-phosphorylated CMTM3 in HER2-overexpressed breast cancer cells.
    Carcinogenesis. 2025 Aug 21:bgaf048. doi: 10.1093.
    

    >> Share

    
    

    
    Clin Breast Cancer

53. FATIREGUN O, Sutradhar R, Podolsky S, Eisen A, et al
    Appropriate Treatment for Stage 1 and 2 Her2-Positive and Triple-Negative Breast Cancer by Immigration Status in Ontario, Canada.
    Clin Breast Cancer. 2025 Jul 18:S1526-8209(25)00209.
    

    >> Share

    
    
54. DE MORAES FCA, Wagner PHS, da Silva ABN, Magalhaes MCF, et al
    Does Epstein-Barr Virus Contribute to Breast Cancer Risk Worldwide? A Systematic Review and Meta-Analysis.
    Clin Breast Cancer. 2025 Jul 17:S1526-8209(25)00212.
    

    >> Share

    
    
55. ANTONINI M, Mattar A, Madeira M, Felix LX, et al
    Prognostic Impact of Real-World Immunohistochemical Changes in Breast Cancer Treated with Neoadjuvant Chemotherapy.
    Clin Breast Cancer. 2025 Jul 30:S1526-8209(25)00220.
    

    >> Share

    
    
56. NAGWANI A, Kapur K, Garg PK
    De-escalating Surgery, Escalating Radiation in Axillary Management of Breast Cancer: Progress or Lateral Shift?
    Clin Breast Cancer. 2025 Aug 5:S1526-8209(25)00226.
    

    >> Share

    
    
57. FEINSTEIN O, Ofer D, Bachmat E, Gazit S, et al
    Short-Term Prediction Model for Breast Cancer Risk Based on One Million Medical Records.
    Clin Breast Cancer. 2025 Jul 29:S1526-8209(25)00223.
    

    >> Share

    
    
58. ALZATE-GRANADOS JP, Nino LF
    Prediction of Overall and Relapse-Free Survival in Triple-Negative Breast Cancer Patients Through Machine Learning-Based Clustering on Clinical Data.
    Clin Breast Cancer. 2025 Jul 29:S1526-8209(25)00224.
    

    >> Share

    
    

    
    Clin Cancer Res

59. PATEL RJS, Wu C, Stowers CE, Mohamed RM, et al
    MRI-based mathematical modeling to predict the response of I-SPY 2 breast cancer patients to neoadjuvant therapy.
    Clin Cancer Res. 2025 Aug 26. doi: 10.1158/1078-0432.CCR-25-0668.
    

    >> Share

    
    
60. GERRATANA L, Reduzzi C, Ren Y, Jeselsohn R, et al
    Circulating tumor cells dynamics after CDK4/6 inhibitor for hormone-receptor positive metastatic breast cancer: a biomarker analysis from the PACE phase II study.
    Clin Cancer Res. 2025 Aug 25. doi: 10.1158/1078-0432.CCR-25-0327.
    

    >> Share

    
    
61. JEON SH, Suh KJ, Jung S, Jeon M, et al
    Proliferation of tumor-related regulatory T cells in circulation dictates efficacy of chemoimmunotherapy in triple-negative breast cancer.
    Clin Cancer Res. 2025 Aug 20. doi: 10.1158/1078-0432.CCR-24-3283.
    

    >> Share

    
    

    
    Curr Treat Options Oncol

62. CHATTOPADHYAY A, Goyal F, Sehrawat A, Sidhu IS, et al
    Revolutionizing Breast Cancer Therapeutics: Intersecting Frontiers of Precision Medicine, Nanotechnology, and Drug Delivery Innovations.
    Curr Treat Options Oncol. 2025 Aug 19. doi: 10.1007/s11864-025-01343.
    

    >> Share

    
    

    
    Eur J Cancer

63. AUTIER P, Jorgensen KJ, Stovring H
    Evaluation of screening mammography effectiveness: The IARC recommendations of 2015 need revision.
    Eur J Cancer. 2025;227:115657.
    

    >> Share

    
    
64. VALENZA C, Curigliano G
    Positioning oral selective estrogen receptor degraders in patients with metastatic breast cancer.
    Eur J Cancer. 2025;228:115739.
    

    >> Share

    
    
65. HAYASHI T, Ogita M, Kakegawa R, Kikawa Y, et al
    Comparison of hypofractionation and conventional fractionation in postmastectomy radiotherapy after immediate breast reconstruction: A systematic review and meta-analysis of complications.
    Eur J Cancer. 2025;227:115669.
    

    >> Share

    
    

    
    Eur J Surg Oncol

66. ABDULLAYEV N, Kottlors J, Habibov H, Yilmaz F, et al
    European guideline informed RAG-based GPT-4 decision support tool in tumor board meetings for breast cancer treatment.
    Eur J Surg Oncol. 2025;51:110384.
    

    >> Share

    
    
67. TAUBER N, Rambow AC, Gasthaus C, Fick F, et al
    Axillary surgery in early breast cancer: real-world analysis of the INSEMA-trial at three certified university breast cancer centers in Germany regarding the omission of sentinel lymph node biopsy.
    Eur J Surg Oncol. 2025;51:110392.
    

    >> Share

    
    

    
    Eur Radiol

68. AZCONA SAENZ J, Molero Calafell J, Roman Exposito M, Vall Foraster E, et al
    Preoperative estimation of the pathological breast tumor size in architectural distortions: a comparison of DM, DBT, US, CEM, and MRI.
    Eur Radiol. 2025;35:5635-5645.
    

    >> Share

    
    
69. KIDOH M, Hirai T
    Reply to the Letter to the Editor: Current role of the pericoronary fat attenuation index in breast cancer patients undergoing chemotherapy.
    Eur Radiol. 2025 Aug 22. doi: 10.1007/s00330-025-11960.
    

    >> Share

    
    
70. ROTZINGER DC, Fahrni G
    Letter to the Editor: Current role of the pericoronary fat attenuation index in breast cancer patients undergoing chemotherapy.
    Eur Radiol. 2025 Aug 22. doi: 10.1007/s00330-025-11959.
    

    >> Share

    
    
71. GIANNOTTI E, Pasculli M, Sella T, Van Ongeval C, et al
    ESR Essentials: post-treatment breast cancer surveillance from mammography to a more personalised approach-practice recommendations by the European Society of Breast Imaging.
    Eur Radiol. 2025 Aug 14. doi: 10.1007/s00330-025-11819.
    

    >> Share

    
    
72. HOVDA T, Larsen M, Bergan MB, Gjesvik J, et al
    Retrospective evaluation of a CE-marked AI system, including 1,017,208 mammography screening examinations.
    Eur Radiol. 2025;35:5685-5694.
    

    >> Share

    
    
73. JU Y, Zhang G, Wan Y, Wang G, et al
    Integration of AI lesion classification, age, and BI-RADS assessment to reduce benign biopsies on breast ultrasound.
    Eur Radiol. 2025;35:5658-5670.
    

    >> Share

    
    

    
    Int J Cancer

74. JOHN EM, Koo J, Keegan TH, Gomez SL, et al
    Reproductive factors and risk of contralateral breast cancer by age and hormone receptor status: The California Breast Cancer Survivorship Consortium.
    Int J Cancer. 2025 Aug 16. doi: 10.1002/ijc.70089.
    

    >> Share

    
    

    
    Int J Oncol

75. ZOU X, Li S, Huang S, Niu R, et al
    Harnessing TP73?targeted nintedanib: A novel strategy to halt triple?negative breast cancer via p53?PPARalpha/PI3K?Akt pathway suppression.
    Int J Oncol. 2025;67:88.
    

    >> Share

    
    

    
    Int J Radiat Oncol Biol Phys

76. NICHOL A, Wade L, Gondara L, Musoke R, et al
    A Matched Case-Control Study of the Relationship Between Radiation Dose to the Internal Mammary Lymph Nodes and Clinical Outcomes in Patients With and Without Internal Mammary Lymph Node Relapses.
    Int J Radiat Oncol Biol Phys. 2025;123:150-160.
    

    >> Share

    
    

    
    J Clin Oncol

77. BIDARD FC, Gessain G, Bachelot T, Frechin L, et al
    Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: Development and Validation of a Clinicopathologic Assay.
    J Clin Oncol. 2025 Aug 22:JCO2500742. doi: 10.1200/JCO-25-00742.
    

    >> Share

    
    
78. WEDAM S, Narayan P, Gittleman H, Cheng J, et al
    US Food and Drug Administration Approval Summary: Inavolisib With Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Locally Advanced or Metastatic Breast
    J Clin Oncol. 2025 Aug 22:JCO2500663. doi: 10.1200/JCO-25-00663.
    

    >> Share

    
    
79. CAI L, Pfob A, Barr RG, Duda V, et al
    Deep Learning Model for Breast Shear Wave Elastography to Improve Breast Cancer Diagnosis (INSPiRED 006): An International, Multicenter Analysis.
    J Clin Oncol. 2025 Aug 20:JCO2402681. doi: 10.1200/JCO-24-02681.
    

    >> Share

    
    

    
    J Natl Cancer Inst

80. YU TT, Hoyt AC, Joines MM, Fischer CP, et al
    Mammographic classification of interval breast cancers and artificial intelligence performance.
    J Natl Cancer Inst. 2025;117:1627-1638.
    

    >> Share

    
    
81. SPOOR J, Mureau MAM, Tissier RLM, Hommes J, et al
    Breast implant illness after reconstruction with silicone breast implants.
    J Natl Cancer Inst. 2025;117:1717-1728.
    

    >> Share

    
    

    
    J Surg Oncol

82. KIM M, Bubberman J, Amakiri U, Kim YS, et al
    Culture Impacts Sexual Well-Being in Autologous Breast Reconstruction: A Multi-Continental Examination.
    J Surg Oncol. 2025;132:375-383.
    

    >> Share

    
    
83. BRABENDER DE, Griffiths A, Lu KA, Armstrong K, et al
    Factors Associated With Residual Positive Lymph Nodes With Targeted Axillary Lymph Node Dissection for Breast Cancer and Accuracy of Clipped Node Retrieval in Non-Mapping Patients.
    J Surg Oncol. 2025 Aug 21. doi: 10.1002/jso.70070.
    

    >> Share

    
    

    
    Mod Pathol

84. MARKEY M, Kim J, Goldstein Z, Gerardin Y, et al
    Spatial Mapping of Gene Signatures in Hematoxylin and Eosin-Stained Images: A Proof of Concept for Interpretable Predictions Using Additive Multiple Instance Learning.
    Mod Pathol. 2025;38:100772.
    

    >> Share

    
    
85. HU Y, Jones D, Zhao W, Tozbikian G, et al
    Incidence, Clinicopathologic Features, and Follow-Up Results of human epidermal growth factor receptor-2-Ultralow Breast Carcinoma.
    Mod Pathol. 2025;38:100783.
    

    >> Share

    
    

    
    Nat Rev Clin Oncol

86. KILLOCK D
    ASTER 70 suggests no clinical benefit from adjuvant chemotherapy in older patients with ER(+)HER2(-) breast cancer.
    Nat Rev Clin Oncol. 2025 Aug 18. doi: 10.1038/s41571-025-01070.
    

    >> Share

    
    

    
    NPJ Breast Cancer

87. MUGO N, Contino G
    Genomic landscapes of breast cancer in African populations: a systematic review.
    NPJ Breast Cancer. 2025;11:91.
    

    >> Share

    
    
88. PONTOLILLO L, Davis AA, Gerratana L, Medford AJ, et al
    Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2- metastatic breast cancer: a retrospective multi-institutional Consortium analysis.
    NPJ Breast Cancer. 2025;11:93.
    

    >> Share

    
    
89. ARONSON J, Bhatta M, Carey LA, Jobanputra K, et al
    Bridging the gap: ctDNA, genomics, and equity in breast cancer care.
    NPJ Breast Cancer. 2025;11:92.
    

    >> Share

    
    

    
    Oncogene

90. MIYAN J, Kumar N, Moinuddin, Malik SA, et al
    Leveraging RAS-mSIN1 interaction to selectively inhibit mTORC2 employing competitive RAS binding peptide: implications in breast cancer metastasis.
    Oncogene. 2025 Aug 23. doi: 10.1038/s41388-025-03516.
    

    >> Share

    
    
91. HAWES ML, Moody MA, McCauley CR, Huddleston AG, et al
    Oncogenic effects of ECM remodeling in obesity and breast cancer.
    Oncogene. 2025 Aug 22. doi: 10.1038/s41388-025-03521.
    

    >> Share

    
    

    
    Oncology (Williston Park)

92. SHEN S, Bethina Liu Md, Chad Fanti Md, Maria Bromberg Mph, et al
    GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast Cancer.
    Oncology (Williston Park). 2025;null:294-296.
    

    >> Share

    
    

    
    PLoS One

93. KHATRI RB, Endalamaw A, Darssan D, Assefa Y, et al
    A scoping review of the levels, implementation strategies, enablers, and barriers to cervical, breast, and colorectal cancer screening among migrant populations in selected English-speaking high-income countries.
    PLoS One. 2025;20:e0329854.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

94. KHAN F, Liu Y, Whitfield D, Pang L, et al
    Macrophage TBK1 signaling drives the development and outgrowth of breast cancer brain metastasis.
    Proc Natl Acad Sci U S A. 2025;122:e2420793122.
    

    >> Share

    
    
95. PADRAO N, Gregoricchio S, Eickhoff N, Dong J, et al
    TRIM24 as a therapeutic target in endocrine treatment-resistant breast cancer.
    Proc Natl Acad Sci U S A. 2025;122:e2507571122.
    

    >> Share

    
    

    
    Radiology

96. VERBOOM SD, Kroes J, Pires S, Broeders MJM, et al
    AI Should Read Mammograms Only When Confident: A Hybrid Breast Cancer Screening Reading Strategy.
    Radiology. 2025;316:e242594.
    

    >> Share

    
    
97. WOOLDRIK SM, van de Voort EMF, Struik GM, Schouten BJM, et al
    Percutaneous Thermal Ablation for Early-Stage Breast Cancer: An Open-Label, Randomized, Phase II Trial to Select the Preferred Technique for Evaluating Thermal Ablation as a Surgical Alternative.
    Radiology. 2025;316:e243386.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share